Xponance Inc. Has $206,000 Stock Holdings in Organon & Co. (NYSE:OGN)

Xponance Inc. boosted its holdings in shares of Organon & Co. (NYSE:OGN) by 15.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 13,828 shares of the company’s stock after acquiring an additional 1,823 shares during the period. Xponance Inc.’s holdings in Organon & Co. were worth $206,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of OGN. Millstone Evans Group LLC bought a new position in shares of Organon & Co. during the fourth quarter worth $29,000. GeoWealth Management LLC bought a new position in shares of Organon & Co. during the fourth quarter worth $41,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Organon & Co. during the first quarter worth $60,000. GAMMA Investing LLC boosted its position in shares of Organon & Co. by 186.9% during the first quarter. GAMMA Investing LLC now owns 4,611 shares of the company’s stock worth $69,000 after purchasing an additional 3,004 shares in the last quarter. Finally, Cary Street Partners Financial LLC bought a new position in shares of Organon & Co. during the fourth quarter worth $111,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 1.9%

Organon & Co. stock opened at $9.46 on Monday. The firm has a market capitalization of $2.46 billion, a PE ratio of 3.28, a P/E/G ratio of 0.98 and a beta of 0.60. The company’s 50-day moving average is $9.52 and its 200-day moving average is $12.49. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $23.10. The company has a debt-to-equity ratio of 16.49, a current ratio of 1.67 and a quick ratio of 1.15.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.13. The company had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a net margin of 11.92% and a return on equity of 227.43%. Organon & Co.’s revenue for the quarter was down 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.22 EPS. Sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 12th. Investors of record on Monday, May 12th were paid a $0.02 dividend. The ex-dividend date was Monday, May 12th. This represents a $0.08 dividend on an annualized basis and a yield of 0.85%. Organon & Co.’s dividend payout ratio (DPR) is currently 2.78%.

Analyst Ratings Changes

Several research firms recently commented on OGN. Morgan Stanley cut their price objective on shares of Organon & Co. from $15.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Monday, May 5th. Piper Sandler cut their price objective on shares of Organon & Co. from $24.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday, May 15th. Evercore ISI cut shares of Organon & Co. from an “outperform” rating to an “inline” rating in a research report on Friday, May 2nd. Finally, BNP Paribas raised shares of Organon & Co. to a “strong-buy” rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Insider Activity at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver acquired 8,045 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was purchased at an average price of $9.21 per share, with a total value of $74,094.45. Following the acquisition, the insider directly owned 52,489 shares of the company’s stock, valued at approximately $483,423.69. This trade represents a 18.10% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Ali acquired 34,000 shares of the business’s stock in a transaction on Monday, May 5th. The stock was acquired at an average cost of $8.80 per share, with a total value of $299,200.00. Following the acquisition, the chief executive officer directly owned 282,731 shares in the company, valued at approximately $2,488,032.80. This trade represents a 13.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 102,345 shares of company stock worth $902,430 in the last quarter. Corporate insiders own 1.40% of the company’s stock.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.